Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Yan Yan , Gilles Montalescot Added: 1 year ago
ESC 23 — Dr Yan Yan (Beijing Anzhen Hospital, CN) and Prof Gilles Montalescot (Pitie Salpetriere APHP University Hospital,FR) discusses the findings from a comparison of anticoagulation prolongation vs no anticoagulation in STEMI patients post-primary PCI (RIGHT) (NCT03664180). The RIGHT study (Beijing Anzhen Hospital) aimed to evaluate the clinical efficacy and safety of anticoagulation… View more
Author(s): Paulus Kirchhof Added: 1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,… View more
Author(s): Oussama M Wazni Added: 6 months ago
AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).OPTION is a prospective, multi-center, multi… View more
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more